These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36018250)

  • 1. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.
    Hanania HL; Lewis DJ
    J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
    Tsung I; Worden FP; Fontana RJ
    Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
    Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
    J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy.
    O'Connell KA; Schmults CD
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 inhibitors for cutaneous squamous cell carcinoma: A meta-analysis.
    Aboul-Fettouh N; Chen L; Ma J; Patel J; Silapunt S; Migden M
    Australas J Dermatol; 2022 Feb; 63(1):36-42. PubMed ID: 34699068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.
    Stevenson ML; Wang CQ; Abikhair M; Roudiani N; Felsen D; Krueger JG; Pavlick AC; Carucci JA
    JAMA Dermatol; 2017 Apr; 153(4):299-303. PubMed ID: 28259107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Life-Saving Response to Anti-PD-1 in a Solid Organ Transplant Recipient With Metastatic Cutaneous Squamous Cell Carcinoma: A Case Report and Review.
    Antonelli JP; Quach M; Mahajan A; Pleva J; Ma VT
    J Immunother; 2024 Jul-Aug 01; 47(6):216-219. PubMed ID: 38532708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection.
    Lipson EJ; Naqvi FF; Loss MJ; Schollenberger MD; Pardoll DM; Moore J; Brennan DC
    Am J Transplant; 2020 Aug; 20(8):2264-2268. PubMed ID: 32185872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
    Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A
    Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of immune checkpoint inhibitors in solid organ transplant recipients with advanced cutaneous malignancies.
    Ji S; Liu H; Pachella L; Stephenson RD; Groisberg R; Weiss SA
    Front Transplant; 2023; 2():1284740. PubMed ID: 38993910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
    Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
    Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
    In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Head and Neck Microvascular Free Tissue Transfer for Advanced Cutaneous Squamous Cell Carcinoma: A Comparison of Solid Organ Transplant Recipients to Nontransplant Patients.
    Wang RY; Gallagher KK; Hernandez DJ; Sandulache VC; Sturgis EM; Huang AT
    J Oral Maxillofac Surg; 2024 Mar; 82(3):347-355. PubMed ID: 38103578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus.
    Gambichler T; Hessam S; Lüttringhaus T; Boms S
    Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
    Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
    Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.
    Vidovic D; Simms GA; Pasternak S; Walsh M; Peltekian K; Stein J; Helyer LK; Giacomantonio CA
    Front Immunol; 2021; 12():678028. PubMed ID: 34122442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of advanced cutaneous squamous-cell carcinoma.
    Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Shrinkage of a Giant Cutaneous Squamous Cell Carcinoma with Immunotherapy in a Kidney Transplant Recipient.
    Eleftheriadis T; Samaras I; Spanos A; Kotsakis A; Stefanidis I
    Exp Clin Transplant; 2023 Jun; 21(6):534-536. PubMed ID: 37455472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature.
    Lu Z; Afzal M; Shirai K
    Transpl Immunol; 2023 Dec; 81():101932. PubMed ID: 37734447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.